Mark D. Minden
Impact in
- Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.1%
Papers in
- Hematology 301
- Acute Myeloid Leukemia Research 244
- Chronic Myeloid Leukemia Treatments 89
- Hematopoietic Stem Cell Transplantation 34
-
- Histone Deacetylase Inhibitors Research 42
- Protein Degradation and Inhibitors 34
- Co-authors
- John E. Dick (55 shared papers)Tsvee Lapidot (4 shared papers)Barbara Murdoch (2 shared papers)Christian Sirard (2 shared papers)Josef Vormoor (2 shared papers)Trang Hoang (2 shared papers)Michael A. Caligiuri (2 shared papers)Bruce M. Paterson (1 shared paper)
- Journals
- Blood (127 papers)Leukemia Research (20 papers)Leukemia (17 papers)Cancer Research (16 papers)British Journal of Haematology (14 papers)
- Partner nations
- CanadaUnited StatesGermany
In The Last Decade
Mark D. Minden
483 papers receiving 23.2k citations
Mark D. Minden's Hit Papers
Peers
Comparison fields: 5 of 169
- Hematology 8.3k
- Genetics 2.9k
- Oncology 7.0k
- Cancer Research 3.7k
- Immunology 4.0k
Countries citing papers authored by Mark D. Minden
This map shows the geographic impact of Mark D. Minden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Minden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Minden more than expected).
Fields of papers citing papers by Mark D. Minden
This network shows the impact of papers produced by Mark D. Minden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Minden. The network helps show where Mark D. Minden may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark D. Minden, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 509 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Hit paper breakdown → | 1994 | 3534 |
| 2 | MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia Hit paper breakdown → | 2001 | 1283 |
| 3 | Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia Hit paper breakdown → | 2012 | 818 |
| 4 | Stem cell gene expression programs influence clinical outcome in human leukemia Hit paper breakdown → | 2011 | 740 |
| 5 | Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations Hit paper breakdown → | 2010 | 558 |
| 6 | Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia Hit paper breakdown → | 2012 | 502 |
| 7 | A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects Hit paper breakdown → | 2018 | 446 |
| 8 | 2007 | 372 | |
| 9 | 2017 | 349 | |
| 10 | 2011 | 340 | |
| 11 | 1991 | 331 | |
| 12 | 2007 | 241 | |
| 13 | 1990 | 214 | |
| 14 | 1985 | 207 | |
| 15 | 1985 | 196 | |
| 16 | 2008 | 194 | |
| 17 | 2004 | 189 | |
| 18 | 2002 | 185 | |
| 19 | 2016 | 183 | |
| 20 | 1999 | 182 |
About Mark D. Minden
Mark D. Minden is a scholar working on Hematology, Molecular Biology, Oncology, Public Health, Environmental and Occupational Health and Genetics, having authored 509 papers that have together received 23.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (244 papers), Chronic Myeloid Leukemia Treatments (89 papers), Acute Lymphoblastic Leukemia research (85 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (43 papers), Histone Deacetylase Inhibitors Research (42 papers), Chronic Lymphocytic Leukemia Research (39 papers), Hematopoietic Stem Cell Transplantation (34 papers) and Protein Degradation and Inhibitors (34 papers). The work is most often cited by research in Hematology (8.3k citations), Genetics (2.9k citations), Oncology (7.0k citations), Cancer Research (3.7k citations) and Immunology (4.0k citations). Mark D. Minden has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include John E. Dick, Tsvee Lapidot, Barbara Murdoch, Christian Sirard, Josef Vormoor, Trang Hoang, Michael A. Caligiuri, Bruce M. Paterson, Julio Roberto Cáceres‐Cortés and Aaron D. Schimmer. Their work appears in journals such as Blood, Leukemia Research, Leukemia, Cancer Research and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.